Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000337111 | SCV000346423 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000390695 | SCV000346424 | uncertain significance | Neuroblastoma | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000278520 | SCV000346425 | uncertain significance | Pheochromocytoma | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000337111 | SCV001559090 | likely benign | Charcot-Marie-Tooth disease type 2 | 2024-08-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004021331 | SCV002665483 | uncertain significance | not specified | 2024-01-16 | criteria provided, single submitter | clinical testing | The c.1020-5delT intronic variant, located in intron 10 of the KIF1B gene, results from a deletion of one nucleotide within intron 10 of the KIF1B gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. The evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear. |